Tryptophan-Induced Eosinophilia–Myalgia Syndrome
- 29 March 1990
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 322 (13) , 926-928
- https://doi.org/10.1056/nejm199003293221309
Abstract
Beginning in the late spring of 1989, large numbers of patients became ill with a disorder first recognized the following October and termed the eosinophilia—myalgia syndrome.1 , 2 Almost all the people affected had taken dietary supplements of tryptophan, a naturally occurring amino acid publicized as useful for the treatment of insomnia, depression, and premenstrual symptoms. The median dose ingested was 1.5 g per day — twice the usual dietary intake. The duration of ingestion varied from a few weeks to several years, and a few patients had stopped taking the tryptophan before their symptoms appeared.As of February 9, 1990, the . . .Keywords
This publication has 7 references indexed in Scilit:
- Scleroderma, Fasciitis, and Eosinophilia Associated with the Ingestion of TryptophanNew England Journal of Medicine, 1990
- Association of the Eosinophilia–Myalgia Syndrome with the Ingestion of TryptophanNew England Journal of Medicine, 1990
- Case 4-1990New England Journal of Medicine, 1990
- Interim Guidance on the Eosinophilia-Myalgia SyndromeAnnals of Internal Medicine, 1990
- Clinical Epidemiology of Toxic-Oil SyndromeNew England Journal of Medicine, 1983
- Development of a Scleroderma-like Illness during Therapy with L-5-Hydroxytryptophan and CarbidopaNew England Journal of Medicine, 1980
- Scleroderma-like Lesions and the Carcinoid SyndromeArchives of internal medicine (1960), 1973